SEC Filing · 4
Soleno Therapeutics, Inc.
SEC Filing
Company context
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗